Results of NurOwn(TM) Clinical Trial Suggest Efficacy in ALS Patients

Results of NurOwn(TM) Clinical Trial Suggest Efficacy in ALS Patients 
Data Indicate Initial Clinical Benefit in Overall Clinical and
Respiratory Function 
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwire) -- 03/21/13 --
 BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of
adult stem cell technologies for neurodegenerative diseases, today
reported some of the final results from a clinical study evaluating
the company's NurOwn(TM) technology in 12 ALS patients. NurOwn is a
proprietary, first-of-its-kind technology for the propagation and
differentiation of autologous Mesenchymal Stem Cells (MSCs) into
NeuroTrophic Factor (NTF)-secreting cells. The data were presented
yesterday, Wednesday, March 20, 2013 during the 65th Annual Meeting
of the American Academy of Neurology (AAN) in San Diego, California. 
An oral and poster presentation were made in the Emerging Science
Session by Principal Investigator Dimitrios Karussis, M.D., Ph.D.,
entitled, "Analysis of 12 Patients with Amyotrophic Lateral Sclerosis
(ALS) Treated with Autologous Differentiated Mesenchymal Stem Cells:
a Phase I/II Clinical Trial." Karussis reported a significantly
slower decline in overall clinical and respiratory function, as
measured by the ALS Functional Rating Score (ALSFRS-R) and Forced
Vital Capacity (FVC) score respectively, in the six patients that
received an intrathecal (IT) injection of the cells in the six months
following treatment, as compared to the three months preceding
treatment. The study concluded that in addition to establishing the
safety of the treatment protocol, initial indications of clinical
benefit were observed, which require further confirmation in
additional trials. The company is currently conducting a Phase IIa
dose-escalating trial pursuant to recent acceleration by the Israeli
Ministry of Health. 
"These encouraging results confirm the importance and therapeutic
potential of NurOwn as a breakthrough treatment for patients with
ALS," said Prof. Karussis, Head of the Neuroimmunology Laboratory,
Department of Neurology, Hadassah Medical Center, Jerusalem.
"Additionally, beyond its benefit in treating patients with ALS,
NurOwn may have utility in the treatment of other severe
neurodegenerative and neuroimmunological conditions includ
ing
multiple sclerosis and Parkinson's disease." 
"We are excited by these data and the potential of NurOwn to
positively impact the lives of patients with ALS," said Alon
Natanson, Chief Executive Officer of BrainStorm. "We look forward to
continuing to advance this potentially important therapy. To that
end, we have begun a Phase IIa dose-escalating trial at Hadassah and
plan to launch a multi-center Phase II trial in the USA later this
year in order to further validate the results that were presented
today." 
About NurOwn(TM)
 NurOwn is an autologous, adult stem cell therapy
technology that differentiates bone marrow-derived mesenchymal stem
cells (MSC) into specialized, neuron-supporting cells. These
neuron-supporting cells (known as "MSC-NTF" cells) secrete
neurotrophic, or nerve-growth, factors for PROTECTION of existing
motor neurons, PROMOTION of motor neuron growth, and RE-ESTABLISHMENT
of nerve-muscle interaction. The ability to differentiate mesenchymal
stem cells into MSC-NTF cells, and confirmation of their activity and
potency before transplantation, makes NurOwn a first-of-its-kind
approach for treating neurodegenerative diseases. More information
about NurOwn(TM) can be found at
http://brainstorm-cell.com/index.php/science-a-technology/-nurown. 
About ALS
 One of the most common neuromuscular diseases worldwide,
Amyotrophic lateral sclerosis (ALS), sometimes called Lou Gehrig's
disease, is a rapidly progressive, invariably fatal neurological
disease that attacks the nerve cells responsible for controlling
voluntary muscles. As many as 30,000 people in the United States have
ALS and an estimated 5,000 Americans are newly diagnosed each year.
The disease belongs to a group of disorders known as motor neuron
diseases, which are characterized by the gradual degeneration and
death of motor neurons. There is currently no cure available for ALS. 
About BrainStorm Cell Therapeutics, Inc.
 BrainStorm Cell
Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
company's website at www.brainstorm-cell.com. 
Safe Harbor Statement - Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at http://www.sec.gov. These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. 
CONTACTS
BrainStorm Cell Therapeutics Inc.
Mr. Alon Natanson
CEO
Phone: +972-3-9236384
info@brainstorm-cell.com
www.brainstorm-cell.com 
LifeSci Advisors, LLC
Michael Rice, Founding Partner
646-597-6979
mrice@lifesciadvisors.com
www.LifeSciAdvisors.com